Your Search Returned 360 tagged news reports
Conducted in eight medical centers in Taiwan, the double-blind, placebo-controlled study randomized 82 patients in 1:1 ratio with 50mg AC-201 or placebo two times each day along with ULT during the treatment period spanning 16 weeks. TWi
Tags:
Audit finds shortcomings in Sarasota's use of neighborhood grant Published: Wednesday, June 5, 2013 at 3:21 p.m...It is dinnertime and teenagers chat on a deck of Janie's Garden Phase II, while children ride bicycles below, past a row of palms and
Tags:
Aimed at advancing the company's first clinical candidate into preclinical studies, the three-year grant will particularly support non-human primate efficacy studies, mechanism of action experiments, and discovery of a next-generation molecule.
Tags:
The study will confirm the product concept of the topical formulation of terbinafine MOB-015 in addition to providing a basis for a Phase III study and out-licensing. Moberg Pharma CEO Peter Wolpert said, "MOB-015 has the potential to become a
Tags:
Saturday, contractors will start shifting traffic along the westbound lanes of Marine Corps Drive in Hagta. * The two outermost lanes currently under construction will open. * The two center lanes of the roadway will be closed for refurbishment and
Tags:
Phase II opportunity continues development of the most promising Phase I concepts. These are visionary aerospace architecture, mission, or system concepts with transformative potential, which continue to push into new frontiers, while remaining
Tags:
With three-monthly sales of $314 million, management reiterated that full-year revenues for 2013 are expected to hit $1.3 billion. Furthermore, note analysts, this figure is on the conservative side a view that has been shaped by an exceptional
Tags:
MRX-6 works by inhibiting a steroid target, sPLA2, and through enriching cell surface glycosaminoglycans (GAG). Celsus chief executive officer Gur Roshwalb said, "Hands treated with MRX-6 demonstrated clinically meaningful improvement. We currently
Tags:
Jeremiah is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. April 18 to a 12-year high of $85.90 per share on April 19 after the company reported positive outcomes from
Tags:
Glassia, for the treatment of congenital emphysema, resulting in a 36% drop in revenue compared with the corresponding quarter of 2012. Kamada's revenue fell to $12.6 million for the first quarter from $19.6 million for the corresponding quarter, and
Tags: